These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36361427)

  • 1. The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis-Cross-Sectional Study.
    Kołtuniuk A; Pytel A; Krówczyńska D; Chojdak-Łukasiewicz J
    Int J Environ Res Public Health; 2022 Nov; 19(21):. PubMed ID: 36361427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
    Al-Keilani MS; Almomani BA
    Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
    J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ; Lemmens WA; Hoogervorst EL; Donders R
    Health Qual Life Outcomes; 2017 Mar; 15(1):50. PubMed ID: 28292329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
    Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
    Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
    Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
    Jongen PJ; Hengstman G; Hupperts R; Schrijver H; Gilhuis J; Vliegen JH; Hoogervorst E; van Huizen M; van Munster E; Samijn J; de Schryver E; Siepman T; Tonk M; Zandbergen E; ten Holter J; van der Kruijk R; Borm G
    BMC Neurol; 2011 Mar; 11():40. PubMed ID: 21450086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to Disease-Modifying Therapies for Multiple Sclerosis.
    Higuera L; Carlin CS; Anderson S
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1394-1401. PubMed ID: 27882830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Lahdenperä S; Soilu-Hänninen M; Kuusisto HM; Atula S; Junnila J; Berglund A
    Acta Neurol Scand; 2020 Dec; 142(6):605-612. PubMed ID: 32559310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing Barriers to Adherence with the Use of Dimethyl Fumarate in Multiple Sclerosis.
    Aungst A; Casady L; Dixon C; Maldonado J; Moreo N; Pearsall L; Robertson D
    Clin Drug Investig; 2020 Jan; 40(1):73-81. PubMed ID: 31599395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
    Kleinman NL; Beren IA; Rajagopalan K; Brook RA
    J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What are the trends in the treatment of multiple sclerosis in recent studies? - A bibliometric analysis with global productivity during 1980-2021.
    Aykaç S; Eliaçık S
    Mult Scler Relat Disord; 2022 Dec; 68():104185. PubMed ID: 36183445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.
    Saiz A; Mora S; Blanco J;
    Neurologia; 2015 May; 30(4):214-22. PubMed ID: 24484756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
    Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
    Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.